New York State Department of Health

PreciseDx's "Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer" Featured in Clinical Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis, today announced that its analytical validation study for its PreciseBreast™ assessment has been published in the November 3, 2023 issue of Clinical Breast Cancer.

Key Points: 
  • Collectively, these studies demonstrated an analytical performance that accurately predicts early-stage breast cancer risk of recurrence within 6 years.
  • PreciseBreast™ is an in vitro prognostic test that predicts breast cancer recurrence for patients diagnosed with early-stage IBC.
  • This latest study builds upon PreciseDx's earlier clinical validation study published in Breast Cancer Research (cited 2022 Dec 21, 24:93.
  • "Our innovative digital assessment holds immense promise in enhancing early-stage breast cancer recurrence prediction, ultimately improving patient care and outcomes.

Castle Biosciences Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023

Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:

Key Points: 
  • Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:
    DecisionDx®-Melanoma test reports delivered in the quarter were 8,559, compared to 7,354 in the third quarter of 2022, an increase of 16%.
  • DecisionDx®-SCC test reports delivered in the quarter were 2,820, compared to 1,636 in the third quarter of 2022, an increase of 72%.
  • MyPath® Melanoma test reports delivered in the quarter were 1,011, compared to 834 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the third quarter of 2022, an increase of 21%.
  • Castle Biosciences will hold a conference call on Thursday, Nov. 2, 2023, at 4:30 p.m. Eastern time to discuss its third quarter 2023 results and provide a corporate update.

Emerest Connect Convenes Top New York State Healthcare Leaders to Address Urgent Needs Among Homebound Patients and Caregivers

Retrieved on: 
Thursday, November 2, 2023

Today, elected leaders from across New York came together at Emerest Connect to discuss urgent issues related to healthcare services, with a particular focus on underserved communities and their caregivers.

Key Points: 
  • Today, elected leaders from across New York came together at Emerest Connect to discuss urgent issues related to healthcare services, with a particular focus on underserved communities and their caregivers.
  • Emerest Connect is a telehealth platform and homecare agency with a patient engagement television studio in the Bronx.
  • The meeting comes at a particularly pivotal moment, as year’s end approaches and New York State legislators begin to plan for the 2024 budget.
  • Homecare and the demand for caregivers have emerged as focal points of the debate, given that New York expects an estimated 932,000 residents to be homebound by 2035.

Findhelp Expands Work with NYC Providers and Health Systems Prior to Launch of the NY State 1115 Medicaid Waiver

Retrieved on: 
Thursday, October 26, 2023

NYC Health + Hospitals (H+H), the nation's largest municipal healthcare system, has partnered with findhelp to connect community members with social care services.

Key Points: 
  • NYC Health + Hospitals (H+H), the nation's largest municipal healthcare system, has partnered with findhelp to connect community members with social care services.
  • The main goals of the waiver are to improve health equity in the Medicaid program, and approval is expected in late fall 2023.
  • Findhelp is also excited to announce our new partnership with Montefiore, one of New York's premier academic health systems.
  • At a United Hospital Fund conference this summer, Amir Bassiri, the Medicaid Director for New York DOH, said that the 1115 Medicaid waiver will integrate social care with health care to support population health, improve health outcomes, and reduce health disparities.

New York State Laboratory Approved for Genetic Testing Using Saliva

Retrieved on: 
Tuesday, October 17, 2023

SYRACUSE, N.Y., Oct. 17, 2023 /PRNewswire/ -- Quadrant Laboratories announced today that its Syracuse-based lab has been approved by the New York State Department of Health for genetic testing. This is in conjunction with the NYSDOH approval of Quadrant's Fragile X Syndrome (FXS) test, which is now available for physicians to order in all 50 states. Quadrant's FXS test uses a saliva swab as a primary collection, rather than a blood draw, and can be collected in the patient's home before getting shipped back to be tested in Quadrant's CLIA/CLEP certified clinical lab.

Key Points: 
  • SYRACUSE, N.Y., Oct. 17, 2023 /PRNewswire/ -- Quadrant Laboratories announced today that its Syracuse-based lab has been approved by the New York State Department of Health for genetic testing.
  • Dr. Funda Suer, EVP of Clinical Diagnostics and Clinical Laboratory Director for Quadrant Laboratories, said, "In both the pediatric and adolescent populations, we found it was much easier to collect saliva versus blood.
  • This genetic condition  is caused by changes in the FMR1 gene, which is responsible for creating a protein crucial in brain development.
  • Following the discovery of the association between the FMR1 gene and FXS, gene-specific testing has made identifying the condition significantly more accurate.

Lovell Communications Welcomes Three Health Care Consultants

Retrieved on: 
Wednesday, October 4, 2023

NASHVILLE, Tenn., Oct. 4, 2023 /PRNewswire/ -- Lovell Communications , an HMA Company, has added three consultants to its growing team of health care communications, public relations and marketing experts.

Key Points: 
  • NASHVILLE, Tenn., Oct. 4, 2023 /PRNewswire/ -- Lovell Communications , an HMA Company, has added three consultants to its growing team of health care communications, public relations and marketing experts.
  • Amanda Shephard joins Lovell as senior account supervisor with an extensive track record in public health campaign development and a deep understanding of omni-channel marketing.
  • Shephard most recently served as senior media advisor for the New York State Department of Health where she managed multimillion-dollar state and local public health and communications campaigns.
  • "The needs and expectations of health systems, provider organizations, public health agencies and consumers continue to accelerate and evolve, and effective communications have never been more important," said Rosemary Plorin, CEO of Lovell Communications.

New York State Approves Pathnostics' Guidance UTI Test

Retrieved on: 
Wednesday, October 4, 2023

IRVINE, Calif., Oct. 4, 2023 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced that its advanced test for urinary tract infections (UTIs) has gained approval from the New York State Department of Health (NYSDOH). The approval broadens patient access to the company's Guidance® UTI test, which enables rapid diagnosis and precise treatment of complicated, recurrent, and persistent UTIs.

Key Points: 
  • The approval broadens patient access to the company's Guidance® UTI test, which enables rapid diagnosis and precise treatment of complicated, recurrent, and persistent UTIs.
  • To learn more about Pathnostics' Guidance UTI test, click here .
  • "We are thrilled that our Guidance UTI test has been approved by an organization renowned for its expertise, high standards, and stringent process for validating clinical lab tests.
  • Earning this approval is a testament to the Guidance UTI test and its impact in addressing a complex health challenge."

NACDD Announces Impact Award Winners and New Board of Directors

Retrieved on: 
Friday, September 29, 2023

ATLANTA, Sept. 29, 2023 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) announced the winners of the 2023 Impact Awards as well as its new Board of Directors during the Annual Business Meeting held Sept. 26.

Key Points: 
  • ATLANTA, Sept. 29, 2023 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) announced the winners of the 2023 Impact Awards as well as its new Board of Directors during the Annual Business Meeting held Sept. 26.
  • The Impact Awards are nominated by NACDD Members and selected by a committee who evaluate the applications to identify the greatest impact on chronic disease prevention and control and health promotion.
  • "The passion, dedication, and innovation shown by NACDD Members across our states and territories is truly inspiring!
  • The newly elected At Large Directors are:
    Victoria Ballares, MSN, DNP, FNP, BLS, a board certified Family Nurse Practitioner in Guam.

Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

Retrieved on: 
Tuesday, September 12, 2023

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh.
  • “Castle is committed to serving patients through high-quality molecular tests that inform important care decisions in the management of conditions with high clinical need,” said Kristen Oelschlager, chief operating officer of Castle Biosciences.
  • “Successful completion of the rigorous New York State licensure process for our Pittsburgh laboratory reflects this commitment and expands our ability to positively impact patient care.”
    Castle operates clinical laboratories in Pittsburgh and Phoenix.
  • The new laboratory in Pittsburgh brings Castle’s total laboratory operations space to more than 52,000 square feet combined.

GUTHRIE CORNING HOSPITAL NAMED PROVISIONAL LEVEL III TRAUMA CENTER

Retrieved on: 
Tuesday, August 29, 2023

Corning, N.Y., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Officials at The Guthrie Clinic announced today that Guthrie Corning Hospital has been designated a Provisional Level III Adult Trauma Center by the New York State Department of Health (NYSDOH), effective August 28, 2023.

Key Points: 
  • Corning, N.Y., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Officials at The Guthrie Clinic announced today that Guthrie Corning Hospital has been designated a Provisional Level III Adult Trauma Center by the New York State Department of Health (NYSDOH), effective August 28, 2023.
  • “Guthrie Corning Hospital now joins Guthrie Robert Packer Hospital and Guthrie Troy Community Hospital as designated/accredited trauma centers,” said Dr. Edmund Sabanegh, President and CEO of The Guthrie Clinic.
  • A Level III Trauma Center increases the level of care available to those facing medical emergencies and provides critical support in emergency situations.
  • Guthrie’s Robert Packer Hospital is an accredited Level I Trauma Center and Guthrie Troy Community Hospital is an accredited Level IV Trauma Center by the Pennsylvania Trauma Systems Foundation.